Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety

PURPOSE: Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40–80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathur, Manoj Chandra, Ratnam, P. Venkat, Saikumar, S.J., John, Manuel, Ravishankar, Siddharth, Dinesh, M.B, Chandil, Priya, Pahuja, Kishore, Cherlikar, Vidya, Wadhwani, Sunny, Bendale, Pankaj, Hazari, Ajit, Mishra, Rajesh, Deshmukh, Susheel, Achlerkar, Rahul Raja, Shah, Devang Tilak, Hingorani, Chanda, Shah, Kaivan, Topiwala, Pratik, Jani, Sheetal, Rana, Viral G., Majumdar, Nilay Kumar, Chakrabarti, Debasis, Dey, Rituparna, Halder, Debabrata, Choudhury, Sumit, Kumar, Ajeet, Das, Sasmita, Nanda, Ashok Kumar, Kumar, Vidya Bhushan, Dubey, Rama, Kamdar, Gulam Ali, Pandey, Alka, Kishanpuria, Sheetal, Srivastava, Rajat Mohan, Singh, Parul, Verma, Sunil Kumar, Sharma, Neha, Gupta, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418014/
https://www.ncbi.nlm.nih.gov/pubmed/37322670
http://dx.doi.org/10.4103/IJO.IJO_25_23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418014/
https://www.ncbi.nlm.nih.gov/pubmed/37322670
http://dx.doi.org/10.4103/IJO.IJO_25_23

Ejemplares similares